Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05425940 · ClinicalTrials.gov registry record · Phase 3

Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

A Phase 3 study of Colorectal Cancer, sponsored by Exelixis.

Active
Registry status
Phase 3
Development phase
901
Enrollment target
20
Study locations

NCT05425940 is a Phase 3 study of Colorectal Cancer that is active but no longer recruiting, run by Exelixis. The registered enrollment target is 901 participants, below the 1,509-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (40% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05425940, a Phase 3 study of Colorectal Cancer, is active but no longer recruiting, sponsored by Exelixis.

ACTIVE NOT RECRUITING
Registry status
Phase 3
Development phase
901 participants
Enrollment target
20
Study locations

Study Summary

The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

Conditions Studied

Colorectal Cancer

Interventions

  • DRUG Atezolizumab
  • DRUG Regorafenib
  • DRUG XL092

Study Locations (20)

California

  • Exelixis Clinical Site #9 - Duarte
  • Exelixis Clinical Site #55 - La Jolla
  • Exelixis Clinical Site #77 - Los Angeles
  • Exelixis Clinical Site #105 - Orange
  • Exelixis Clinical Site #80 - Santa Monica
  • Exelixis Clinical Site #5 - Santa Rosa
  • Exelixis Clinical Site #82 - Sylmar
  • Exelixis Clinical Site #58 - Torrance
  • Exelixis Clinical Site #81 - Whittier

Arizona

  • Exelixis Clinical Site #30 - Phoenix
  • Exelixis Clinical Site #70 - Tucson

Florida

  • Exelixis Clinical Site #16 - Miami Beach
  • Exelixis Clinical Site #60 - Orlando

Alabama

  • Exelixis Clinical Site #65 - Jonesboro

Connecticut

  • Exelixis Clinical Site #125 - New Haven

Georgia

  • Exelixis Clinical Site #4 - Marietta

Illinois

  • Exelixis Clinical Site #3 - Joliet

Indiana

  • Exelixis Clinical Site #102 - Indianapolis

Trial Details

FieldValue
Enrollment Target 901 participants
Start Date 2022-09-07
Est. Completion 2027-01
Phase Phase 3

Sponsor

Exelixis

48 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05425940

The ClinicalTrials.gov registry entry for NCT05425940 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 901 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,509-participant average among 369 other Colorectal Cancer trials with a reported enrollment target (40% lower). The listed sponsor is Exelixis, which has 48 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Atezolizumab is the first listed.

NCT05425940 reports 20 study locations spanning 10 distinct geographic areas - top geographies include California, Arizona, Florida.

Frequently Asked Questions

What is clinical trial NCT05425940 about?

NCT05425940 is a clinical study titled "Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer". The primary purpose of this study is to evaluate XL092 + atezolizumab versus regorafenib in participants with microsatellite stable/microsatellite instability low (MSS/MSI-low) metastatic colorectal cancer (mCRC) who have progressed during, after or are intolerant to standard-of-care (SOC) therapy.

What is the current status of trial NCT05425940?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 901 participants. The study started on 2022-09-07. Estimated completion is 2027-01.

What conditions does trial NCT05425940 study?

This clinical trial studies the following conditions: Colorectal Cancer.

What interventions are being tested in trial NCT05425940?

The interventions under investigation include: Atezolizumab (DRUG), Regorafenib (DRUG), XL092 (DRUG).

Who is sponsoring clinical trial NCT05425940?

This trial is sponsored by Exelixis, which has 48 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05425940 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Connecticut, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Colorectal Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Colorectal Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.